RxDoctor Payments Data

Kari Sierant

Adult Health · Morristown, NJNPI 1184149940

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Johnson & Johnson at 53.8% of the total. Reporting peaked in 2023 at $3,897 and has fallen 71.4% since, to $1,113 in 2025. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,418in general payments, 2019–2025

Across 241 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$5K
  • AbbVie$420
  • Incyte Corporation$384
  • Pfizer$293
  • AstraZeneca$284
  • GSK$267
  • plus $3K from 43 others

What the payments were for

  • Consulting fees$4,64049%
  • Food & beverage$4,03643%
  • Education$7138%
  • Other$280%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,418 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,936
Medicare patients
302
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate11$378,995
IbrancePalbociclib23$307,989
EliquisApixaban72$65,160
XareltoRivaroxaban28$27,171
Anastrozole164$3,176
Gabapentin36$716
Letrozole36$637
Hydroxyurea15$448
Imatinib Mesylate13$337
Omeprazole29$273
Prednisone17$49
Escitalopram Oxalate14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$267$378,99511 claims
PfizerIbrance, Eliquis$293$373,14995 claims
Johnson & JohnsonXarelto$5,070$27,17128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →